ASCO 2013 acceptance makes CTIX official and provides the credibility needed to move forward.
I've been watching Cellceutix for some time now, and have been tempted to buy multiple times. I like the association with Dana Farber, and Scientific Advisory board comprised of prominent folks at Sloan Kettering. But I always had this lingering concern about purchasing and OTC stock. Today's ASCO 2013 acceptance of the Kevetrin poster was the piece of data I needed to make a buy decision. Seldom do you get in on the ground floor of a major paradigm shift in oncology treatment, but Cellceuitix at this level appears to afford that opportunity. I feel very comfortable my investment today will do quite well over the coming year.
i have similar concerns and similar reasons for supporting this company, except when i got in not long ago, i did not know of the asco application. i am currently holding over 150k shares, thinking it is extremely undervalued and under-recognized.
one thing i foresee is that the good science will do the talking. hard core lab data will be our friend.
Right now is a perfect time to either add or buy for the first time. Just the fact that farber is even looking for p21 marker in the dosing level is unbelievable. If you invest in biotech, this this tells you that the prestigous Harvard strongly believes in the potential of Kevetrin.
People say that Prurisol is the next catalyst but I am watching the toxicity and dosing studies of Kevetrin. Every report and update on this is can be a significant catalyst. From everything I have read, it looks good, but the uncertainty is always there in biotech. Right now CTIX is just looking for the MTD, DLT-dose limiting toxcities and esablish a very safe dose for Phase II and other studies by both sponsors and Cellceutix. Secondarily: They are looking at how the body absorbs the drug and the metabolic actions/mechanisms. Of course, simultaneously they will look at Kevetrins antitumor effects, even at these escalating doses, and the so called Holy Grail would be if Kevetrin can induce changes in the biomarker P21. This would definitely put Cellceutix on the Map for good and would probably lure many investors who like biomgr11 have been watching on the sidelines. As CEO Leo said "This would be a Home Run." Also, simultaneously they are observing how Kevetrin reacts with the microorganisms within the body and how it effects receptors and which receptors are effected and to what extent they are effected.
So there is a lot to keep in mind with this escalating Phase I study.
Prurisol for Psoriasis, is an ester of an alread approved drug. Animal studies demostrated very, very good results...close to a cure. Since it is an ester of an already approved drug this gives Kevetrin the option to file a NDA under rule 505 (b)(2), in short expedites the approval process because safey and tolerability have already been proven. Since the disease involves TNF -tumor necrosis factor and Th1 inflammatory cytokine response, I personally have always thought that Effective Psoriasis drugs can